Irritability clinical trials

Explore recruiting irritability clinical trials.

Recruiting irritability studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Irritability trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents with Irritability Associated with Autism Spectrum Disorder (ASD)

Spain, Poland, France, Italy, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder

Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X syndrome: an N-of-1 series

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents, and Young Adults with Fragile X Syndrome - RECONNECT

Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

C4801002 - A Phase 2, Randomized, Open-Label Trial to Describe the Safety and Immunogenicity of A Monovalent Pneumococcal Conjugate Candidate Administered As a 2-Dose Series in Healthy Toddlers 12 Through 15 Months of Age Who Previously Received PCV10 Primary Series in the European Union

Finland, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndrome

Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Irritability trials by city

Irritability in Toronto Irritability in Vancouver Irritability in Montreal Irritability in Calgary Irritability in Edmonton Irritability in Ottawa Irritability in Winnipeg Irritability in Quebec City Irritability in Hamilton Irritability in Kitchener Irritability in London Irritability in Halifax Irritability in New York Irritability in Los Angeles Irritability in Chicago Irritability in Houston

Irritability clinical trials

Recruiting irritability studies right now

Mechanism of FODMAP Restriction on FGID Patients

A Practice Change for Patients With Severe Chronic, Clinically Unexplained Gastrointestinal Symptoms

Sucrase-Isomaltase (SI) Genes and Meal Load

Digestive Enzyme Formulation Intervention in IBS Patients Who Previously Clinically Responded to Mediterranean LFD

Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients

Vit-A-Vision® Clinical Investigation

Brachyspira and Intestinal Allergy-like Immune Reactions in Patients With Irritable Bowel Syndrome (IBS)

Efficacy of a Low FODMAP Diet in the Absence of Lactose Malabsorption in Moderate to Severe ROME IV IBS.

Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial

Ebastine Versus Mebeverine in IBS Patients

Efficacy of Esketamine for Patients With Irritable Bowel Syndrome

ConfocAl endomicroSCopy bAsed Diet Trial in IBS

Also recruiting in Europe

A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents with Irritability Associated with Autism Spectrum Disorder (ASD)

A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 years of age) with Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 years of age) with Irritability Associated with Autism Spectrum Disorder

Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X syndrome: an N-of-1 series

A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents, and Young Adults with Fragile X Syndrome - RECONNECT

C4801002 - A Phase 2, Randomized, Open-Label Trial to Describe the Safety and Immunogenicity of A Monovalent Pneumococcal Conjugate Candidate Administered As a 2-Dose Series in Healthy Toddlers 12 Through 15 Months of Age Who Previously Received PCV10 Primary Series in the European Union

An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndrome

Irritability trials by city

Other conditions